Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-1 of 1
Keywords: Anifrolumab
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Immunology and Allergy
Laura Anna Bokor, Katalin Martyin, Máté Krebs, Noémi Ágnes Galajda, Fanni Adél Meznerics, Bence Szabó, Péter Hegyi, Kende Lőrincz, Norbert Kiss, András Bánvölgyi, Bernadett Hidvégi
Journal:
Kompass Autoimmun
Kompass Autoimmun (2025) 7 (2): 59–67.
Published Online: 10 April 2025
... (OR: 2,54, 95%-KI: 1,20–5,40) und Anifrolumab (OR: 2,25, 95%-KI: 1,23–4,14) waren signifikant wirksamer als ein Placebo. Es gab keine signifikanten Unterschiede in der Häufigkeit von AE und SAE zwischen diesen Behandlungen und dem Placebo. Schlussfolgerung: Anifrolumab und Litifilimab sind wirksame und...
